GlobeNewswire

Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone

Share

CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has received confirmation from the U.S. Food and Drug Administration ("FDA") that BETonMACE, Resverlogix's on-going Phase 3 study, if successful, is likely to support the filing and approval of a New Drug Application ("NDA"). The statistical analysis plan and endpoints proposed by the Company were reviewed and accepted by the Division of Cardiovascular and Renal Products ("DcaRP") of the FDA. The exact indication to be sought by the Company, and to be reviewed by the FDA, would be driven by the study's results.

The ongoing Phase 3 BETonMACE trial has enrolled its planned target of over 2,400 patients. The trial patients are high-risk cardiovascular disease ("CVD") patients with type 2 Diabetes Mellitus ("DM") and low levels of high-density lipoprotein ("HDL") who have recently (within 7-90 days) experienced an acute coronary syndrome (myocardial infarction or unstable angina). These patients are at very high CVD risk despite standard of care treatment. The primary endpoint of the BETonMACE trial is designed to establish a relative risk reduction ("RRR") of Major Adverse Cardiac Events ("MACE"), narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction or stroke. BETonMACE is an event-driven trial, and with recruitment complete, continues to accumulate MACE towards the required number.

"We are excited to receive feedback from the FDA that confirms the path forward for filing of an NDA for apabetalone, the first selective BET inhibitor for the treatment of high-risk cardiovascular disease. The FDA's feedback is similar to that received previously from European authorities. We are now focused on completing the BETonMACE study together with other activities required for NDA and Marketing Authorisation Application ("MAA") filings," stated Donald McCaffrey, President and CEO of Resverlogix.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low levels of high-density lipoprotein (HDL). In BETonMACE approximately 11% of the participants have chronic kidney disease.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX

For further information please contact:

Investor Relations
Email:ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the BETonMACE study, the filing and approval of an NDA and/or MAA, and  the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Resverlogix Corp via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Corline Biomedical AB presenterar på Redeyes Growth Day 202026.5.2020 13:54:48 CESTPressemelding

Den 2 juni kl 14.00 presenterar​ ​Henrik Nittmar, VD i Corline Biomedical AB​ den senaste utvecklingen i bolaget på Redeye. Presentationen livesänds och kan följas på https://www.redeye.se/live/growth-day-2020​ där presentationen även i efterhand kommer finnas tillgänglig, s​amt på vår bolagssida i Redeye Universe https://www.redeye.se/company/corline-biomedical. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: henrik.nittmar@corline.se Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: ca@skmg.se Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administrati

Corline Biomedical AB presenterar på Redeyes Temaevent Orphan Drugs26.5.2020 13:49:07 CESTPressemelding

Corline Biomedical AB (”Corline”) kommer att presentera sin verksamhet på Redeyes temaevent Orphan Drugs. Presentationen sker kl 11:30 den 27 maj 2020 i Stockholm och livesänds via Redeyes hemsida. Konferensprogrammet och livesändningen görs tillgängliga via Redeyes hemsida https://www.redeye.se/live/orphan-27-maj. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: henrik.nittmar@corline.se Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: ca@skmg.se Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administration av Corlines heparinsubstans och sedan tidigare

Lundin Gold Inc. Announces C$50 Million Bought Deal Financing26.5.2020 13:30:02 CESTPress release

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION TO UNITED STATES VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) -- Lundin Gold Inc. ("Lundin Gold" or the "Company") (TSX: LUG, Nasdaq Stockholm: LUG) has announced today that it has entered into an agreement with BMO Capital Markets (“BMO”), under which BMO has agreed to buy on a bought deal basis 4,150,000 common shares (the “Common Shares”), at a price of C$12.05 per Common Share for gross proceeds of approximately C$50 million (the “Offering”). The Company has granted BMO an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. The offering is expected to close on or about June 11, 2020 and is subject to Lundin Gold receiving all necessary regulatory approvals. Newcrest Mining Limited, which currently holds approximately 32% of the Company’s issued and outsta

PCI Biotech: Disclosure of voting rights for Chairman of the Board26.5.2020 13:20:03 CESTPress release

Oslo, 26 May 2020. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 27 May 2020. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 7,171,710 additional shares. In total, Mr. Bøhn will represent and vote for 19.6 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 27 May 2020. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757

Prosafe SE: First quarter 2020 report – Adapting to a new reality26.5.2020 11:44:38 CESTPress release

(Figures in brackets refer to the corresponding period of 2019) After several years of low activity across the industry, the company has presented a business plan and a restructuring proposal to lenders which – if approved as proposed – will result in a sustainable balance sheet. The revised business plan reflects a new reality in light of Covid-19, structural changes, oil price collapse, oversupply and anticipated impact on future activity and performance. Consequently, an impairment of USD 810.5 million was made to the book value of vessels in the quarter resulting in a negative book equity of USD 858.9 million by the end of the quarter. The company has sufficient liquidity of USD 184 million at the end of the quarter and continues to operate on a going concern basis on the assumption that there is justified hope to agree a sustainable financial solution with lenders. Recent highlights Prosafe implemented Covid-19 plans early to safeguard people and assets, and this has proven succes

Result of Riksbank reversed auctions SEK Municipal Bonds26.5.2020 11:30:00 CESTPress release

Result of Riksbank reversed auctions SEK Municipal Bonds Results of auctions Municipal BondsAggregateAuction date5/26/2020Maturity2022Tendered volume, mln SEK750 +/- 750Volume offered, mln SEK1,600Volume bought, mln SEK100Number of bids4Number of accepted bids1Credit Class 1Maturity, QuarterQ1Maturity, QuarterQ2Maturity, QuarterQ3Maturity, QuarterQ4Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Number of bids0Number of bids0Number of bids0Number of bids0Number of accepted bids0Number of accepted bids0Number of accepted bids0Number of accepted bids0Average yield-Average yield-Average yield-Average yield-Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Highest yield-Highest yield-Highest yield-Highest yield-% accepted at lowest yield-% accepted at lowest yield-% accepted at lowest yield-% accepted at lowest yie